117 related articles for article (PubMed ID: 23978293)
1. PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study.
Karlsen RV; Larsen SB; Christensen J; Brasso K; Friis S; Tjønneland A; Dalton SO
Acta Oncol; 2013 Nov; 52(8):1609-14. PubMed ID: 23978293
[TBL] [Abstract][Full Text] [Related]
2. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study.
Hjertholm P; Fenger-Grøn M; Vestergaard M; Christensen MB; Borre M; Møller H; Vedsted P
Int J Cancer; 2015 Jan; 136(2):435-42. PubMed ID: 24905402
[TBL] [Abstract][Full Text] [Related]
3. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
4. Correlates of prostate-specific antigen testing in a large multiethnic cohort.
Haque R; Van Den Eeden SK; Jacobsen SJ; Caan B; Avila CC; Slezak J; Sternfeld B; Loo RK; Quinn VP
Am J Manag Care; 2009 Nov; 15(11):793-9. PubMed ID: 19895183
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.
Hayat Roshanai A; Nordin K; Berglund G
Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929
[TBL] [Abstract][Full Text] [Related]
6. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
[TBL] [Abstract][Full Text] [Related]
7. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase.
Kristal AR; Chi C; Tangen CM; Goodman PJ; Etzioni R; Thompson IM
Cancer; 2006 Jan; 106(2):320-8. PubMed ID: 16342294
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
9. Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL.
Ladjevardi S; Berglund A; Varenhorst E; Bratt O; Widmark A; Sandblom G
BJU Int; 2013 Mar; 111(3):381-8. PubMed ID: 22758210
[TBL] [Abstract][Full Text] [Related]
10. Effects of an Educational Program for Prostate Cancer Prevention on knowledge and PSA Testing in Men Over 50 Years old in Community Areas of Shiraz in 2016.
Molazem Z; Ebadi M; Khademian M; Zare R
Asian Pac J Cancer Prev; 2018 Mar; 19(3):633-637. PubMed ID: 29580031
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark.
Jønler M; Eddy B; Poulsen J
Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092
[TBL] [Abstract][Full Text] [Related]
13. Associations of demographic and health-related characteristics with prostate cancer screening in Washington State.
Close DR; Kristal AR; Li S; Patterson RE; White E
Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):627-30. PubMed ID: 9681532
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
18. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer incidence and survival in relation to education (United States).
Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M
Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
D'Amico AV; Renshaw AA; Sussman B; Chen MH
JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
